Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

GSK and Save the Children Partner to Help Africa

Published: Friday, May 10, 2013
Last Updated: Friday, May 10, 2013
Bookmark and Share
Currently, nearly 7 million children under five die every year from preventable diseases.

In the last ten years, significant progress has been made globally to reduce the rate of child deaths, however more needs to be done to prevent children dying unnecessarily. While the needs of the world’s poorest children are diverse, there are three areas where urgent attention could help to ensure that every child receives essential healthcare:

•    More healthcare workers in these regions
•    Vaccines and medicines
•    Simple nutritious food

Making a change

We are embarking on an ambitious global partnership with Save the Children to share our expertise and resources and focus on these three areas in order to make a lasting change for the world’s most vulnerable children.

The new partnership goes well beyond the traditional charity corporate fundraising model. It will touch many areas of our business, in particular using our R&D capabilities to help save children’s lives.

The GSK and Save the Children partnership will focus in particular on:

•    developing child-friendly medicines to reduce child mortality and new-born deaths
•    widening vaccination coverage to reduce the number of child deaths in the hardest to reach communities
•    researching new affordable nutritional products to help alleviate malnutrition in children
•    increasing investment in the training, reach and scope of health workers in the poorest communities to help reduce child mortality

Beginning with programmes in the Democratic Republic of Congo (DRC) and Kenya, we plan to develop programmes to tackle child mortality and to establish models that can be adopted, expanded and replicated in other developing countries.

Our ambition is to share a blueprint for a new way of working, transforming the traditional fundraising NGO/corporate model. The scale, breadth and ambition of this global partnership far exceeds anything that GSK or Save the Children have done before.

Together, we’ll also use our influence to call for improved policy and practice, and increased international investment in children’s health.

GSK and Save the Children in DRC

The first of our joint programmes – the ‘Integrated project for the battle against childhood diseases’ - will be rolled out in the DRC. Devastated by political and social instability for decades, the DRC is experiencing one of the worst humanitarian crises in the world. It is ranked 187th out of 187 countries in the Human Development Index and life expectancy is low at just 46 years old. The majority of the population lack access to basic services and half of the 66 million population live on less than $1 a day.

The health challenges in DRC, including high levels of infectious diseases, are made more difficult because of gaps in human resources at all levels of the health system – there is just one doctor and only five nurses per 10,000 people. Child mortality rates are among the highest in Africa, with over 400, 000 children dying before the age of five each year, mainly from preventable diseases.

Working with Save the Children, the government of DRC and communities, the programme will deliver an integrated package of essential services for neonatal, maternal and child health. This will include strengthening current systems and infrastructure, to ensure that basic health and nutrition services, and  equipment, supplies and suitably trained staff are accessible to effectively treat common childhood diseases.

GSK has committed £9m to support this programme, which began in April 2013.

GSK and Save the Children in Kenya

Nearly 25% of the 39 million people who live in Kenya survive on less than $1.25 a day, and of those more than 40% are under 15 years old. Across the country, one child in ten dies before their fifth birthday and in the slums of the capital Nairobi and the rural north, this figure is much higher.

Through our partnership we have committed to support Save the Children Kenya’s newborn child survival programme. The programme will focus on improving health systems in order to reduce preventable diseases and to address under five child mortality. In addition to funding this programme, we are making a significant investment through Save the Children’s business, prioritising and progressing the research and development of vital medicines and products to reduce preventable diseases and child mortality.

We have committed over £4m to support this programme, and development is in the early stages. Funding will start later in 2013.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GSK Publishes Promising New Data for COPD Drug
Pioneering GSK study provides important new data on the effectiveness of Relvar Ellipta (FF/VI) when used in everyday clinical practice.
Wednesday, May 25, 2016
Zymeworks, GSK Enter Second Strategic Collaboration
Zymeworks has announced that it has entered into a new licensing agreement with GSK for the research, development, and commercialization of novel bi-specific antibodies enabled using Zymeworks’ Azymetric™ drug discovery platform.
Wednesday, April 27, 2016
SBP, GSK Create New Center for Translational Neuroscience
Academic-industry alliance seeks to find and validate new targets for drug development.
Thursday, April 21, 2016
GSK Won't Seek Drug Patents in Poor Countries
Company expands graduated approach to patents and intellectual property to widen access to medicines in the world’s poorest countries.
Friday, April 01, 2016
VBI, GSK Collaborate
VBI Vaccines has entered into a research collaboration with GlaxoSmithKline Biologicals SA (“GSK”) to evaluate VBI’s LPV™ Platform. VBI’s LPV Platform is a proprietary formulation and process that enables the development of vaccines and biologics with improved stability and preserved potency.
Wednesday, February 10, 2016
GSK Strengthens HIV Drug Pipeline
Two transactions further strengthen HIV pipeline and outlook.
Tuesday, December 22, 2015
GSK Receives Positive CHMP Opinion in Europe for Asthma Therapeutic
GlaxoSmithKline has announced that the CHMP of the EMA has issued a positive opinion recommending marketing authorisation for mepolizumab, which will be commercialised under the brand name Nucala, as an add-on treatment for severe refractory eosinophilic asthma in adult patients.
Monday, September 28, 2015
GSK, Francis Crick Institute Collaborate
This partnership sets out to explore new avenues of medical research and drug discovery across a broad range of diseases, with a view to achieving breakthroughs in the understanding of human disease.
Monday, July 20, 2015
GSK’s 2015 Discovery Fast Track Challenge
Challenge seeks early drug discovery partnerships with academics in Europe, Canada and US.
Wednesday, March 25, 2015
GSK to Invest £200 Million in UK Manufacturing
The series of investments will support the delivery of the company’s pipeline of new medicines and create a centre for pharmaceutical manufacturing innovation in the UK.
Thursday, December 12, 2013
GSK and the Bill & Melinda Gates Foundation to Accelerate Research into Vaccines
The joint initiative will endeavour to make vaccines more resistant to heat, thus reducing the need for refrigeration.
Wednesday, October 30, 2013
Malaria Vaccine Could be Available from 2015
GSK candidate reduces disease over 18 Months of follow-up in late-stage study of more than 15,000 infants and young children.
Tuesday, October 08, 2013
Funding boost for GSK’s Open Innovation Research
GSK announced a funding injection of up to £5m from the Wellcome Trust to support its open approach to discovering and developing new treatments for diseases of the developing world.
Wednesday, May 08, 2013
GSK Gives Update on Plans to Share Detailed Clinical Trial Data
New online system will enable researchers to request access to patient level data from GSK clinical trials to help further scientific understanding and improve patient care.
Wednesday, May 08, 2013
GSK Provides Update on Corporate Responsibility Commitments in 2011 Report
Company publishes its Corporate Responsibility Report, in which it reiterates its commitment to operate responsibly, openly and transparently and sets out advances made on this agenda during 2011.
Monday, April 16, 2012
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
New NIH-EPA Research Centers to Study Environmental Health Disparities
Scientists will partner with community organizations to study these concerns and develop culturally appropriate ways to reduce exposure to harmful environmental conditions.
Structure of Essential Digestive Enzyme Uncovered
Using a powerful combination of techniques from biophysics to mathematics, researchers have revealed new insights into the mechanism of a liver enzyme that is critical for human health.
Air Pollution Linked to Heart Disease
10-year project revealed air pollutants accelerate plaque build-up in arteries to the heart.
Getting a Better Look at How HIV Infects and Takes Over its Host Cells
A new approach, developed by a team of researchers led by The Rockefeller University and The Aaron Diamond AIDS Research Center (ADARC), offers an unprecedented view of how a virus infects and appropriates a host cell, step by step.
Following Tricky Triclosan
Antibacterial product flows through streams, crops.
Vitamin A May Help Improve Pancreatic Cancer Chemotherapy
The addition of high doses of a form of vitamin A could help make chemotherapy more successful in treating pancreatic cancer, according to an early study by Queen Mary University of London (QMUL).
Poverty Marks a Gene, Predicting Depression
New study of high-risk teens reveals a biological pathway for depression.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!